Mark Cheah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Cheah has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Ennaliza Salazar
Department of Gastroenterology and Hepatology Singapore General Hospital Singapore
2 shared publications B. B. George Goh
Department of Gastroenterology & Hepatology Singapore General Hospital Singapore Singapore
1 shared publicationBee Poh
Singapore General Hospital
1 shared publicationBenedix Sim
1 shared publication- Chee-Kiat Tan
Department of Gastroenterology and Hepatology Singapore General Hospital Singapore Singapore
1 shared publication Garrett Kang
Singapore General Hospital
1 shared publication
Latest Publications
- Open Access
- 16 February 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 1-2
Shaping the MASLD Evidence Base? Rethinking Geographic and Gender Representation in the Literature
- 16 February 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (7) , 1-2
Open AccessShaping the MASLD Evidence Base? Rethinking Geographic and Gender Representation in the Literature
- 13 August 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (1) , 153-154
Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
- 13 August 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (1) , 153-154
Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
- Open Access
- 14 March 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (3) , 607-618
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis
Background: Metabolic Dysfunction-Associated Fatty Liver disease (MAFLD) among lean individuals is increasingly recognized. We aimed to compare the prevalence, metabolic characteristics, and outcomes of lean vs overweight/obese-MAFLD patients. Methods: Databases of Embase, Medline, and Web of Science were searched from inception till October 2023. Only cohorts adhering to the lean-MAFLD criteria as defined by the international consensus statement were included. Results: In the pooled analysis of 10,013,382 individuals, the prevalence of lean-MAFLD in the general population was 1.94% (95% CI 1.10–3.39%, I 2 = 98.7%). Lean and overweight/obese-MAFLD patients had similar metabolic characteristics for blood pressure, LDL, TG, blood glucose, and HbA1c. There was an increased incidence rate and likelihood for liver-related mortality for lean-MAFLD vs overweight/obese-MAFLD [1.33 per 1000 patient-years (95% CI 1.28–1.39) vs 0.76 (95% CI 0.25–2.28), (OR 3.56 (95% CI 3.45–3.67), p < 0.01). There were similar incidence rates and odds ratios between lean vs overweight/obese-MAFLD for: (1) all-cause mortality [10.08 per 1000 patient-years (95% CI 9.93–10.23) vs 8.94 per 1000 patient-years (95% CI 4.08–19.57), (OR 1.92 (95% CI 0.01–220.57), p = 0.33)]; (2) cardiovascular-related mortality [2.53 per 1000 patient-years (95% CI 0.65–9.96) vs 2.07 per 1000 patient-years (95% CI 0.80–5.39), (OR 1.91 (95% CI 0.02–142.76), p = 0.58)]; and (3) cancer-related mortality [3.42 per 1000 patient-years (95% CI 3.33–3.51) vs 3.15 per 1000 patient-years (95% CI 1.21–8.19), (OR 1.99 (95% CI 0.29–13.52), p = 0.13). Conclusion: Lean-MAFLD patients have an equivalent metabolic burden compared to overweight/obese-MAFLD patients and thus a similar incidence rate of major extrahepatic complications. However, they have an increased risk of liver-related mortality. Graphical
- 14 March 2025
- Published by Springer Nature in Hepatology International
- Vol. 19 (3) , 607-618
Open AccessGlobal prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis
Background: Metabolic Dysfunction-Associated Fatty Liver disease (MAFLD) among lean individuals is increasingly recognized. We aimed to compare the prevalence, metabolic characteristics, and outcomes of lean vs overweight/obese-MAFLD patients. Methods: Databases of Embase, Medline, and Web of Science were searched from inception till October 2023. Only cohorts adhering to the lean-MAFLD criteria as defined by the international consensus statement were included. Results: In the pooled analysis of 10,013,382 individuals, the prevalence of lean-MAFLD in the general population was 1.94% (95% CI 1.10–3.39%, I 2 = 98.7%). Lean and overweight/obese-MAFLD patients had similar metabolic characteristics for blood pressure, LDL, TG, blood glucose, and HbA1c. There was an increased incidence rate and likelihood for liver-related mortality for lean-MAFLD vs overweight/obese-MAFLD [1.33 per 1000 patient-years (95% CI 1.28–1.39) vs 0.76 (95% CI 0.25–2.28), (OR 3.56 (95% CI 3.45–3.67), p < 0.01). There were similar incidence rates and odds ratios between lean vs overweight/obese-MAFLD for: (1) all-cause mortality [10.08 per 1000 patient-years (95% CI 9.93–10.23) vs 8.94 per 1000 patient-years (95% CI 4.08–19.57), (OR 1.92 (95% CI 0.01–220.57), p = 0.33)]; (2) cardiovascular-related mortality [2.53 per 1000 patient-years (95% CI 0.65–9.96) vs 2.07 per 1000 patient-years (95% CI 0.80–5.39), (OR 1.91 (95% CI 0.02–142.76), p = 0.58)]; and (3) cancer-related mortality [3.42 per 1000 patient-years (95% CI 3.33–3.51) vs 3.15 per 1000 patient-years (95% CI 1.21–8.19), (OR 1.99 (95% CI 0.29–13.52), p = 0.13). Conclusion: Lean-MAFLD patients have an equivalent metabolic burden compared to overweight/obese-MAFLD patients and thus a similar incidence rate of major extrahepatic complications. However, they have an increased risk of liver-related mortality. Graphical
- Open Access
Linitis Plastica in a Patient With Previous Breast Cancer: Primary Gastric Cancer or Breast Cancer Metastases?
Background: Linitis plastica is a challenging diagnosis in the setting of a patient with previous breast cancer.Case presentation: We present a case of a 74‐year‐old Chinese Female with a history of breast cancer who presented with epigastric pain, nausea, early satiety, and weight loss of 5 kg in 3 months. Endoscopic diagnosis of linitis plastica was made, but subsequent management plans were dependent on accurate histological assessment in view of her oncological history.Discussion and conclusion: Our case highlights the clinical conundrum confronting the endoscopist in evaluating suspected linitis plastica where the imaging, endoscopic, and macroscopic histological findings between primary gastric adenocarcinoma and metastatic breast cancer can be indistinguishable. Optimal deep tissue acquisition is required to differentiate the true diagnosis in such cases.
Open AccessLinitis Plastica in a Patient With Previous Breast Cancer: Primary Gastric Cancer or Breast Cancer Metastases?
Background: Linitis plastica is a challenging diagnosis in the setting of a patient with previous breast cancer.Case presentation: We present a case of a 74‐year‐old Chinese Female with a history of breast cancer who presented with epigastric pain, nausea, early satiety, and weight loss of 5 kg in 3 months. Endoscopic diagnosis of linitis plastica was made, but subsequent management plans were dependent on accurate histological assessment in view of her oncological history.Discussion and conclusion: Our case highlights the clinical conundrum confronting the endoscopist in evaluating suspected linitis plastica where the imaging, endoscopic, and macroscopic histological findings between primary gastric adenocarcinoma and metastatic breast cancer can be indistinguishable. Optimal deep tissue acquisition is required to differentiate the true diagnosis in such cases.
- Open Access
- 12 October 2022
- Published by Springer Nature in Research Square
Parenteral nutrition in acute intestinal failure amongst the elderly was not associated with adverse clinical outcomes when compared to younger patients
Introduction: Reported clinical outcomes for elderly patients with acute intestinal failure receiving parenteral nutrition (PN) in the acute hospital setting is limited. Our study aims to characterize the use of PN in the elderly and compare clinical outcomes against younger patients. Methods: A retrospective review of inpatients administered PN from 1st January 2019 to 31st December 2019 was performed. Demographics, indications for PN, biochemical results and clinical outcomes were compared. Patients were categorized into < 65 (younger) or ≥ 65 years old (elderly). Results: 235 patients were included. There were 103 patients in the elderly group with a mean age of 73.9 years (± 6.9 years) and 132 patients in the younger group with a mean age of 52.4 years (± 12.5 years). There was a significantly higher Charlson Comorbidity Index and comordities and lower Karnofsky score in the elderly group. Indications for PN were similar between both groups. There was more younger patients who required PN for ≥28 days. The elderly group received a significantly lower total calorie, dextrose and protein compared to the younger group (20.8 (7.8) vs 22.8 (6.3) kcal/kg/day ; 3.1 (1.4) vs 3.6 (1.4) g/kg/day ; 1.1 (0.4) vs 1.2 (0.3) g/kg/day ). Mean length of stay was significantly longer in the younger group than in the elderly group (59.8 (± 55.3 ) vs 35.9 (± 21.3) days). There was no significant difference in clinical outcomes: line sepsis, hypoglycemia, hyperglycemia, fluid overload, inpatient mortality and total mortality between the two groups. Conclusion: The usage of PN in elderly patients with acute intestinal failure was not associated with an increased rate of PN related complications nor worse clinical outcomes when compared with younger patients. and hence should not be denied when appropriate indications are present.
- 12 October 2022
- Published by Springer Nature in Research Square
Open AccessParenteral nutrition in acute intestinal failure amongst the elderly was not associated with adverse clinical outcomes when compared to younger patients
Introduction: Reported clinical outcomes for elderly patients with acute intestinal failure receiving parenteral nutrition (PN) in the acute hospital setting is limited. Our study aims to characterize the use of PN in the elderly and compare clinical outcomes against younger patients. Methods: A retrospective review of inpatients administered PN from 1st January 2019 to 31st December 2019 was performed. Demographics, indications for PN, biochemical results and clinical outcomes were compared. Patients were categorized into < 65 (younger) or ≥ 65 years old (elderly). Results: 235 patients were included. There were 103 patients in the elderly group with a mean age of 73.9 years (± 6.9 years) and 132 patients in the younger group with a mean age of 52.4 years (± 12.5 years). There was a significantly higher Charlson Comorbidity Index and comordities and lower Karnofsky score in the elderly group. Indications for PN were similar between both groups. There was more younger patients who required PN for ≥28 days. The elderly group received a significantly lower total calorie, dextrose and protein compared to the younger group (20.8 (7.8) vs 22.8 (6.3) kcal/kg/day ; 3.1 (1.4) vs 3.6 (1.4) g/kg/day ; 1.1 (0.4) vs 1.2 (0.3) g/kg/day ). Mean length of stay was significantly longer in the younger group than in the elderly group (59.8 (± 55.3 ) vs 35.9 (± 21.3) days). There was no significant difference in clinical outcomes: line sepsis, hypoglycemia, hyperglycemia, fluid overload, inpatient mortality and total mortality between the two groups. Conclusion: The usage of PN in elderly patients with acute intestinal failure was not associated with an increased rate of PN related complications nor worse clinical outcomes when compared with younger patients. and hence should not be denied when appropriate indications are present.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Su1624: UTILITY OF THE MALNUTRITION UNIVERSAL SCREENING TOOL (MUST) AMONGST AMBULATORY IBD PATIENTS – A PROSPECTIVE ASIAN COHORT
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Su1624: UTILITY OF THE MALNUTRITION UNIVERSAL SCREENING TOOL (MUST) AMONGST AMBULATORY IBD PATIENTS – A PROSPECTIVE ASIAN COHORT
- 18 January 2021
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 29 (4) , 261-270
Virtual monitoring for stable chronic hepatitis B patients does not reduce adherence to medications: A randomised controlled study
Chronic hepatitis B (CHB) remains common in endemic regions, causing significant healthcare burden. Patients with CHB may need to be adherent to nucleoside analogue (NA) for a long period of time to prevent complications. This study aims to investigate the safety, efficacy and patient experience of a virtual monitoring clinic (VMC) in monitoring stable patients taking NA for CHB. Patients on NA and regular follow-up were randomised to either VMC alternating with doctors’ clinic visit or to a control group in which they continued standard follow-up by doctors. Therapy adherence was measured by medication possession ratio (MPR) for NA therapy, incidence of virological breakthrough and hepatocellular carcinoma (HCC) development at two years of follow-up. Patient acceptance was measured on a Likert scale of 1–10. A total 192 patients completed follow-up: 94 and 98 patients in the VMC and control groups, respectively. Mean age was 60.6 ± 10.8 years, with 95.3% Chinese ethnicity and 64.1% males. Age, gender, race, educational, employment and financial status were similar in both groups. Upon study completion, the majority of patients – 76 (80.9%) in VMC group and 74 (75.5%) in control group – had MPR ≥0.8; 88.8% were satisfied and rated VMC better than a traditional follow-up clinic with doctors only. More than 85% of patients rated ≥8/10 on the Likert scale for VMC, and preferred VMC over traditional clinic visits. Clinical outcomes observed were HCC development in one (1.1%) in the VMC group and four (4.1%) in the control group (p = 0.369). Two (2.1%) and one (1.0%) virological breakthroughs were observed in the VMC and control groups, respectively (p = 0.615). No incidence of HCC or abnormal blood tests were missed in the VMC arm. VMC is a viable and safe clinical model for monitoring stable CHB patients on NA therapy without compromising patients’ adherence to medications and is preferred by patients.
- 18 January 2021
- Published by SAGE Publications in Journal of Telemedicine and Telecare
- Vol. 29 (4) , 261-270
Virtual monitoring for stable chronic hepatitis B patients does not reduce adherence to medications: A randomised controlled study
Chronic hepatitis B (CHB) remains common in endemic regions, causing significant healthcare burden. Patients with CHB may need to be adherent to nucleoside analogue (NA) for a long period of time to prevent complications. This study aims to investigate the safety, efficacy and patient experience of a virtual monitoring clinic (VMC) in monitoring stable patients taking NA for CHB. Patients on NA and regular follow-up were randomised to either VMC alternating with doctors’ clinic visit or to a control group in which they continued standard follow-up by doctors. Therapy adherence was measured by medication possession ratio (MPR) for NA therapy, incidence of virological breakthrough and hepatocellular carcinoma (HCC) development at two years of follow-up. Patient acceptance was measured on a Likert scale of 1–10. A total 192 patients completed follow-up: 94 and 98 patients in the VMC and control groups, respectively. Mean age was 60.6 ± 10.8 years, with 95.3% Chinese ethnicity and 64.1% males. Age, gender, race, educational, employment and financial status were similar in both groups. Upon study completion, the majority of patients – 76 (80.9%) in VMC group and 74 (75.5%) in control group – had MPR ≥0.8; 88.8% were satisfied and rated VMC better than a traditional follow-up clinic with doctors only. More than 85% of patients rated ≥8/10 on the Likert scale for VMC, and preferred VMC over traditional clinic visits. Clinical outcomes observed were HCC development in one (1.1%) in the VMC group and four (4.1%) in the control group (p = 0.369). Two (2.1%) and one (1.0%) virological breakthroughs were observed in the VMC and control groups, respectively (p = 0.615). No incidence of HCC or abnormal blood tests were missed in the VMC arm. VMC is a viable and safe clinical model for monitoring stable CHB patients on NA therapy without compromising patients’ adherence to medications and is preferred by patients.